DexCom, Inc. (NASDAQ:DXCM) Holdings Decreased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 34.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 646,846 shares of the medical device company's stock after selling 342,894 shares during the period. Assenagon Asset Management S.A. owned about 0.17% of DexCom worth $50,305,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Thoroughbred Financial Services LLC purchased a new position in shares of DexCom during the second quarter worth about $211,000. Envestnet Asset Management Inc. grew its stake in shares of DexCom by 0.6% in the second quarter. Envestnet Asset Management Inc. now owns 599,303 shares of the medical device company's stock worth $67,949,000 after purchasing an additional 3,356 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in DexCom by 16.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company's stock worth $276,538,000 after purchasing an additional 353,019 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in DexCom by 41.3% in the second quarter. Dimensional Fund Advisors LP now owns 919,650 shares of the medical device company's stock worth $104,282,000 after buying an additional 268,802 shares during the period. Finally, Perennial Investment Advisors LLC lifted its stake in shares of DexCom by 7.4% in the 2nd quarter. Perennial Investment Advisors LLC now owns 3,156 shares of the medical device company's stock valued at $358,000 after purchasing an additional 217 shares during the period. Institutional investors own 97.75% of the company's stock.

DexCom Price Performance

DXCM traded up $4.44 during midday trading on Thursday, reaching $84.84. 5,998,762 shares of the company's stock were exchanged, compared to its average volume of 3,834,166. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The business's 50-day moving average price is $77.89 and its 200 day moving average price is $78.41. The stock has a market capitalization of $33.14 billion, a PE ratio of 50.80, a P/E/G ratio of 2.00 and a beta of 1.12.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DXCM. Wells Fargo & Company lifted their price objective on DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a research note on Wednesday, December 11th. Royal Bank of Canada decreased their price objective on DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Citigroup upped their target price on shares of DexCom from $85.00 to $91.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and lifted their price objective for the company from $86.00 to $104.00 in a research report on Thursday. Finally, Oppenheimer cut their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Six research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, DexCom presently has an average rating of "Moderate Buy" and an average target price of $99.29.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the firm's stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares of the company's stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.30% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.